RET and neoplasm: Although their efficacy against the tumor and despite their activity against RET, the first-generation MKIs approved for the treatment of MTC (i.e., vandetanib and cabozantinib) were limited in their use by the onset of the off-target toxicities (40, 100, 110, 135).